**Abstract**

The risk of antidepressant treatment versus the risk of major depression itself on the development of the fetus is a long-term subject of debates. Particularly important are possible delayed consequences on mental well-being which can occur later in life. The aim of the present studies was to verify the hypothesis that perinatal exposure to venlafaxine has impact on hormones involved in stress coping as well as on anxiety and depression-like behaviour of adult offspring.

Dams were treated orally with one of three doses of venlafaxine or placebo starting on day 15 of gestation until day 21 post partum. At that time, pups were weaned and caged in groups according to gender. As adult, both male and female offspring were subjected to behavioural tests to measure anxiety and depression-like behaviours. Concentrations of corticosterone and aldosterone were analysed by radioimmunoassay in blood obtained by decapitation under non-stress conditions in the morning.

Plasma corticosterone concentrations were higher in females than in males and they were enhanced in offspring of both genders exposed periatally to venlafaxine (significant main factors gender and treatment by two-way ANOVA). Post-hoc analysis showed that venlafaxine exposure-induced enhancement of plasma corticosterone was particularly strong in females exposed to the lowest (7.5mg/kg) and the highest (75mg/kg) dose. Exposure to venlafaxine resulted also in a mild increase in plasma aldosterone (main factor treatment), particularly in males from the highest dose group. On the other hand, exposure to venlafaxine led to reduced anxiety and depression-like behaviour as shown by several variables in elevated plus maze, light-dark box and forced swim tests.

In conclusion, treatment with venlafaxine during gravidity and lactation may result in positive consequences on signs of anxiety and depression in adult offspring associated with only mild increase in stress hormone levels. *Supported by grants VEGA2/0168/15, VEGA2/0057/15 and partly by APVV-14--0840*
